Evans John M.

CEO, DirectorBeam Therapeutics Inc. (BEAM) · full profile →Form 4 · filed Feb 2, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$1.4M
Net Open-Market Flow
-$1.4M
Transactions
11
7 non-derivative · 4 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 30, 2026Sell(S)3K$29.00$84K987K
Jan 30, 2026Sell(S)22K$28.27$625K990K
Jan 30, 2026Option exercise(M)25K$0.67$17K1.0M
Jan 29, 2026Option exercise(M)19K$0.67$13K1.0M
Jan 29, 2026Option exercise(M)6K$0.67$4K1.0M
Jan 29, 2026Sell(S)16K$29.19$477K995K
Jan 29, 2026Sell(S)9K$29.74$258K987K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 31, 2026Grant(A)180K$0180K
Jan 30, 2026Option exercise(M)25K$069K
Jan 29, 2026Option exercise(M)19K$00
Jan 29, 2026Option exercise(M)6K$094K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-033600) within minutes of acceptance. Every field above traces to the original document. Verify it directly: